(Q38183786)

30 August 2017

Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer (English)

1 reference

peritoneal carcinomatosis

30 August 2017

1 reference

1 reference

4

Soichiro Ishihara

1 reference

30 August 2017

Shigenobu Emoto

1

1 reference

30 August 2017

Eiji Sunami

2

1 reference

30 August 2017

Hironori Yamaguchi

3

1 reference

30 August 2017

Joji Kitayama

5

1 reference

30 August 2017

Toshiaki Watanabe

6

1 reference

30 August 2017

1 February 2014

1 reference

30 August 2017

1 reference

30 August 2017

44

1 reference

30 August 2017

12

1 reference

30 August 2017

2209-2220

1 reference

Significant prognostic factors in patients with Stage IV gastric cancer with special reference to the curability of surgery

30 August 2017

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Peritoneal mesothelioma: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Intraperitoneal antineoplastic drug delivery: rationale and results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Drug delivery systems for intraperitoneal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Recent advances in the research of lymphatic stomata

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Hyperthermic intraperitoneal chemotherapy: nomenclature and modalities of perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Early postoperative intraperitoneal chemotherapy following cytoreductive surgery in patients with very advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Surgical treatment for peritoneal carcinomatosis from gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

For the clinical application of thermochemotherapy given at mild temperatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Paclitaxel and its formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Safety of intraperitoneal administration of paclitaxel after gastrectomy with en-bloc D2 lymph node dissection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Comparison of intraperitoneal with intravenous administration of taxol in experimental peritoneal carcinomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Pharmacology of intraperitoneal CPT-11

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Epithelial cell adhesion molecule expression (CD326) in cancer: a short review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Pattern and prognostic factors in patients with malignant ascites: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Nanocarriers as an emerging platform for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Nanoparticle therapeutics: an emerging treatment modality for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Preclinical and clinical studies of anticancer agent-incorporating polymer micelles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Drug penetration in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Delivering nanomedicine to solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Polymer conjugates: nanosized medicines for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Polymer conjugates as anticancer nanomedicines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

The performance of expansile nanoparticles in a murine model of peritoneal carcinomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Enhanced solubility of paclitaxel using water‐soluble and biocompatible 2‐methacryloyloxyethyl phosphorylcholine polymers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

In situ cross-linkable hyaluronic acid hydrogels prevent post-operative abdominal adhesions in a rabbit model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

The prevention of peritoneal adhesions by in situ cross-linking hydrogels of hyaluronic acid and cellulose derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Environment-sensitive hydrogels for drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Suppression of in vivo tumor growth by using a biodegradable thermosensitive hydrogel polymer containing chemotherapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Drug release behaviors of a pH sensitive semi-interpenetrating polymer network hydrogel composed of poly(vinyl alcohol) and star poly[2-(dimethylamino)ethyl methacrylate]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-014-0848-X

Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma

21 January 2018

1 reference

12 December 2020

Administration in a hypotonic solution is preferable to dose escalation in intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in rats

1 reference

12 December 2020

Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy

1 reference

12 December 2020

Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer

1 reference

12 December 2020

Peritoneal absorption of macromolecules studied by quantitative autoradiography

1 reference

12 December 2020

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs

1 reference

12 December 2020

Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery

1 reference

12 December 2020

Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer

1 reference

12 December 2020

Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer

1 reference

12 December 2020

Long-term survival of peritoneal carcinomatosis of colorectal origin

1 reference

12 December 2020

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

1 reference

12 December 2020

Neoadjuvant treatment of gastric cancer with peritoneal dissemination

1 reference

12 December 2020

Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis

1 reference

12 December 2020

Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer

1 reference

12 December 2020

Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer

1 reference

12 December 2020

Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when?

1 reference

12 December 2020

Peritoneal-plasma barrier.

1 reference

12 December 2020

Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study.

1 reference

12 December 2020

Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy

1 reference

12 December 2020

Intraperitoneal treatment using taxol is effective for experimental peritoneal carcinomatosis in a rat model

1 reference

12 December 2020

A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix

1 reference

12 December 2020

Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer

1 reference

12 December 2020

Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration

1 reference

12 December 2020

Phase II Trial of Paclitaxel in Patients with Advanced Colon Cancer Previously Untreated with Cytotoxic Chemotherapy: An Eastern Cooperative Oncology Group Trial (PA286)

1 reference

12 December 2020

Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer

1 reference

12 December 2020

Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients

1 reference

12 December 2020

Multimodal treatment approaches for peritoneal carcinosis in colorectal cancer

1 reference

12 December 2020

Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer

1 reference

12 December 2020

Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes

1 reference

12 December 2020

VEGF significance in peritoneal recurrence from gastric cancer

1 reference

12 December 2020

Markedly elevated levels of vascular endothelial growth factor in malignant ascites

1 reference

12 December 2020

Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study

1 reference

12 December 2020

Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis

1 reference

12 December 2020

Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case-control study

1 reference

12 December 2020

Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study

1 reference

12 December 2020

Cross-linked hyaluronic acid hydrogel films: new biomaterials for drug delivery

1 reference

12 December 2020

Epithelial ovarian cancer

1 reference

12 December 2020

Tumoricidal effects of etoposide incorporated into solid lipid nanoparticles after intraperitoneal administration in Dalton's lymphoma bearing mice

1 reference

12 December 2020

Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle--a new strategy against peritoneal dissemination of gastric cancer

1 reference

12 December 2020

Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination

1 reference

12 December 2020

Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis

1 reference

12 December 2020

New hepatectomy-induced postoperative adhesion model in rats, and evaluation of the efficacy of anti-adhesion materials

1 reference

12 December 2020

Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach?

1 reference

12 December 2020

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

12 December 2020

Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis

1 reference

12 December 2020

Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma

1 reference

12 December 2020

Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies

1 reference

12 December 2020

Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms

1 reference

12 December 2020

10.1007/S00595-014-0848-X

Identifiers

DOI

1 reference

30 August 2017

1 reference